Ovid Therapeutics Files 8-K
Ticker: OVID · Form: 8-K · Filed: 2024-07-01T00:00:00.000Z
Sentiment: neutral
Topics: 8-K, regulatory-filing
TL;DR
Ovid Therapeutics filed an 8-K, check for updates.
AI Summary
Ovid Therapeutics Inc. filed an 8-K on July 1, 2024, to report other events. The filing does not contain specific details about the nature of these events, dollar amounts, or definitive dates beyond the filing date itself.
Why It Matters
This filing indicates that Ovid Therapeutics Inc. has made a regulatory submission to the SEC, which may contain material information about the company's operations or strategic direction.
Risk Assessment
Risk Level: low — The filing is a standard procedural document without immediate financial or operational disclosures that would indicate a high risk.
Key Players & Entities
- Ovid Therapeutics Inc. (company) — Registrant
- July 1, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- New York (location) — Principal Executive Offices City
FAQ
What specific event(s) are being reported in this 8-K filing?
The filing is categorized under 'Other Events' but does not specify the exact nature of the event(s) within the provided text.
When was this 8-K filing submitted to the SEC?
The filing was submitted on July 1, 2024.
What is the principal executive office address for Ovid Therapeutics Inc.?
The principal executive offices are located at 441 Ninth Avenue, 14th Floor, New York, New York 10001.
What is Ovid Therapeutics Inc.'s IRS Employer Identification Number?
The IRS Employer Identification Number for Ovid Therapeutics Inc. is 46-5270895.
Under which section of the Securities Exchange Act of 1934 is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 451 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-07-01 08:04:04
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share OVID The Nasdaq Stock Market
Filing Documents
- ovid-20240701.htm (8-K) — 29KB
- ovid20241julexhibit991.htm (EX-99.1) — 24KB
- duallogoa.jpg (GRAPHIC) — 48KB
- 0001628280-24-030546.txt ( ) — 249KB
- ovid-20240701.xsd (EX-101.SCH) — 2KB
- ovid-20240701_lab.xml (EX-101.LAB) — 22KB
- ovid-20240701_pre.xml (EX-101.PRE) — 13KB
- ovid-20240701_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. On July 1, 2024, Ovid Therapeutics Inc. issued a press release with Graviton Bioscience Corporation announcing Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibit Exhibit No. Description 99.1 Press Release, dated July 1, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OVID THERAPEUTICS INC. By: /s/ Jeffrey Rona Jeffrey Rona Chief Business and Financial Officer Dated: July 1, 2024